TheStreet lowered shares of ICU Medical (NASDAQ:ICUI) from a b- rating to a c+ rating in a research note issued to investors on Monday morning, TheStreetRatingsTable reports.
A number of other equities research analysts have also issued reports on the company. BidaskClub lowered ICU Medical from a buy rating to a hold rating in a research note on Wednesday. Zacks Investment Research lowered ICU Medical from a hold rating to a sell rating in a research note on Wednesday. ValuEngine lowered ICU Medical from a hold rating to a sell rating in a research note on Thursday, August 8th. Finally, Raymond James lowered ICU Medical from a strong-buy rating to an outperform rating in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company. ICU Medical has an average rating of Hold and an average target price of $290.50.
ICUI stock opened at $167.02 on Monday. ICU Medical has a 1 year low of $160.00 and a 1 year high of $312.45. The firm has a market cap of $3.50 billion, a P/E ratio of 21.66 and a beta of 0.81. The stock has a 50-day simple moving average of $237.52 and a 200-day simple moving average of $236.09.
In other ICU Medical news, insider Kevin J. Mcgrody sold 7,344 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $231.68, for a total transaction of $1,701,457.92. Following the completion of the sale, the insider now owns 7,574 shares in the company, valued at approximately $1,754,744.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Robert S. Swinney sold 239 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $248.73, for a total value of $59,446.47. Following the sale, the director now owns 19,662 shares of the company’s stock, valued at approximately $4,890,529.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,661 shares of company stock valued at $8,354,148. 11.40% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its stake in ICU Medical by 1.3% during the 1st quarter. Rhumbline Advisers now owns 45,901 shares of the medical instruments supplier’s stock valued at $10,985,000 after purchasing an additional 575 shares in the last quarter. Texas Permanent School Fund lifted its holdings in ICU Medical by 3.8% during the 1st quarter. Texas Permanent School Fund now owns 11,274 shares of the medical instruments supplier’s stock worth $2,698,000 after buying an additional 414 shares during the last quarter. Raymond James Trust N.A. lifted its holdings in ICU Medical by 47.4% during the 1st quarter. Raymond James Trust N.A. now owns 1,480 shares of the medical instruments supplier’s stock worth $354,000 after buying an additional 476 shares during the last quarter. ARP Americas LP bought a new position in ICU Medical during the 1st quarter worth approximately $212,000. Finally, WCM Investment Management LLC bought a new position in ICU Medical during the 1st quarter worth approximately $1,512,000. Hedge funds and other institutional investors own 91.31% of the company’s stock.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.